Search results for "COMB"

showing 10 items of 7115 documents

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review…

2021

Ceftolozane-tazobactam (C/T) is a combination of an advanced-generation cephalosporin (ceftolozane) with a &beta

0301 basic medicine<i>pseudomonas aeruginosa</i>Biochemistrypseudomonas aeruginosasepsis0302 clinical medicinesystematic reviewceftolozanepolycyclic compoundsPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsceftolozane-tazobactamAnti-infective agentInfectious DiseasesMeta-analysisCeftolozanemedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapySepsiβ-lactamase inhibitors030106 microbiologyMicrobiologyTazobactamArticleSepsis03 medical and health sciencesmultidrug resistanceInternal medicinemedicineMeta-analysibacteremiabusiness.industryorganic chemicalslcsh:RM1-950Retrospective cohort studybiochemical phenomena metabolism and nutritionmedicine.diseasebacterial infections and mycosesinfectionmeta-analysisPneumonialcsh:Therapeutics. PharmacologyESBLESBLsBacteremiabacteriaanti-infective agentsbusiness
researchProduct

Consequences of single-locus and tightly linked genomic architectures for evolutionary responses to environmental change

2020

AbstractGenetic and genomic architectures of traits under selection are key factors influencing evolutionary responses. Yet, knowledge of their impacts has been limited by a widespread assumption that most traits are controlled by unlinked polygenic architectures. Recent advances in genome sequencing and eco-evolutionary modelling are unlocking the potential for integrating genomic information into predictions of population responses to environmental change. Using eco-evolutionary simulations, we demonstrate that hypothetical single-locus control of a life history trait produces highly variable and unpredictable harvesting-induced evolution relative to the classically applied multi-locus mo…

0301 basic medicineAcademicSubjects/SCI011400106 biological sciencesLinkage disequilibriumMultifactorial Inheritanceevolutionary simulationEnvironmental changeGenetic LinkageJhered/401 natural sciencesGenetics (clinical)recombination rate0303 health scienceseducation.field_of_studystructural genomic variationInheritance (genetic algorithm)Adaptation PhysiologicalBiological Evolutionclimate changePerspectiveTraitympäristönmuutoksetBiotechnologyPopulationevoluutioEnvironmentBiology010603 evolutionary biologyLife history theory03 medical and health sciencesVDP::Matematikk og Naturvitenskap: 400::Basale biofag: 470GeneticsEvolutionary dynamicseducationMolecular BiologySelection (genetic algorithm)030304 developmental biologygeenitModels GeneticGenetic Driftilmastonmuutoksetgenetic architectureGenetic architectureEditor's Choice030104 developmental biologyEvolutionary biologyperimäGene-Environment InteractionAdaptationlinkage disequilibrium
researchProduct

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease

2018

Celiac disease (CD) is an autoimmune/inflammatory condition triggered by dietary gluten intake in genetically predisposed individuals. Though associations with MHC class II HLA-DQ2 or -DQ8 are the primary and necessary genetic predisposition for CD, >97% of genetically predisposed individuals never develop CD. Cytokines were measured in the serum of CD patients and controls. Possible associations with IL10 promoter variants were investigated. Cytokine expression from PBMCs was monitored in response to gluten exposure, or CD3/TCR complex stimulation in the absence or presence of recombinant IL-10. Serum cytokines varied between patients with CD at the time of diagnosis, after dietary elimina…

0301 basic medicineAdolescentGenotypeGlutensCD3medicine.medical_treatmentImmunologySystemic inflammationPolymorphism Single NucleotidePeripheral blood mononuclear celllaw.invention03 medical and health sciences0302 clinical medicinelawGenetic predispositionmedicineHumansImmunology and AllergyGenetic Predisposition to DiseaseChildPromoter Regions GeneticInflammationchemistry.chemical_classificationbiologybusiness.industryInterleukin-17GlutenInterleukin-10Celiac DiseaseInterleukin 10030104 developmental biologyCytokineHaplotypeschemistryChild PreschoolImmunologybiology.proteinRecombinant DNACytokines030211 gastroenterology & hepatologymedicine.symptombusinessClinical Immunology
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

A single preoperative pain neuroscience education: Is it an effective strategy for patients with carpal tunnel syndrome?

2019

Patients undergoing carpal tunnel release surgery may continue to experience pain despite the intervention. This symptom may be modulated by psychosocial factors including depression, catastrophic thinking, and kinesiophobia. Pain neuroscience education (PNE) has been found to be effective when combined with therapeutic exercise in patients with chronic pain, but this strategy has not been evaluated in patients with persistent hand pain. The findings of this study indicate that a single preoperative PNE session in combination with therapeutic exercise does not provide added benefits in comparison to standard preoperative care plus therapeutic exercise. Future studies should evaluate if pati…

0301 basic medicineAdultKinesiophobiaPreoperative care03 medical and health sciences0302 clinical medicineDouble-Blind MethodPatient Education as TopicIntervention (counseling)Preoperative CaremedicineCarpal tunnel releaseHumansCarpal tunnel syndromeDepression (differential diagnoses)Physical Therapy ModalitiesAgedbusiness.industryCatastrophizationChronic painNeurosciencesGeneral MedicineMiddle Agedmedicine.diseaseHandCarpal Tunnel SyndromeCombined Modality TherapyExercise Therapy030104 developmental biologyTreatment OutcomePhobic DisordersPreoperative PeriodFemaleChronic PainbusinessNeurosciencePsychosocial030217 neurology & neurosurgeryMedical hypotheses
researchProduct

Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology.

2016

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt;&lt;i&gt;Dermatophagoides pteronyssinus&lt;/i&gt; is one of the most important perennial allergen sources worldwide. Molecular diagnostics using the commercially available major allergens (Der p 1 and Der p 2) in combination with Der p 10 do not detect house dust mite (HDM) sensitization in a number of cases when used alone. The objective was to evaluate the IgE reactivity profiles of these patients using an experimental immunoassay biochip. &lt;b&gt;&lt;i&gt;Methods: &lt;/i&gt;&lt;/b&gt;Sera of HDM-allergic patients (positive skin prick test, CAP class ≥1 for allergen extract, and positive intranasal provocation) were tested for IgE antibodi…

0301 basic medicineAdultMaleAdolescentImmunologymedicine.disease_causeImmunoglobulin ESerologylaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineAllergenlawmedicineHypersensitivityImmunology and AllergyAnimalsHumansSerologic TestsAntigens DermatophagoidesChildAgedbiologybusiness.industryHouse dust mite allergyPyroglyphidaeGeneral MedicineAllergensImmunoglobulin EMiddle Aged030104 developmental biology030228 respiratory systemImmunologybiology.proteinRecombinant DNAFemalebusinessLife studyInternational archives of allergy and immunology
researchProduct

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denm…

2016

BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries.RESULTS: Overall, 59,154 patients …

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtyAdjuvant chemotherapyColorectal cancerPopulationDiseasePopulation-basedStage II03 medical and health sciences0302 clinical medicinePharmacotherapySDG 3 - Good Health and Well-beingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsJournal ArticlemedicineHumansStage (cooking)educationInternational comparisonAgedGynecologyeducation.field_of_studyRelative survivalbusiness.industryResearch Support Non-U.S. Gov'tMiddle Agedmedicine.diseaseSurvival AnalysisColon cancerAdjuvant chemotherapyEurope030104 developmental biologyLogistic ModelsOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsSurgeryFemalebusinessStage ii colon cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study.

2016

Abstract Purpose The aim of this study was to evaluate the efficacy and tolerability of lacosamide (LCM) both as add-on therapy and monotherapy in patients with temporal lobe epilepsy (TLE) based on an observational, prospective, multicenter study. Methods We enrolled 100 patients (mean age: 43.4 ± 12.53 years, 57 females) with nonlesional TLE and TLE with hippocampal sclerosis (HS) that did not respond to the first drug and who were referred to epilepsy centers of the University of Catanzaro, University of Palermo, IRCSS Neuromed of Pozzilli, and Otto-von-Guericke University of Magdeburg. In this open-label, multicenter trial, patients were initiated on oral LCM as add-on therapy to first …

0301 basic medicineAdultMalemedicine.medical_specialtyLacosamideCohort Studies03 medical and health sciencesBehavioral NeuroscienceEpilepsyYoung Adult0302 clinical medicineLacosamideMulticenter trialInternal medicineAcetamidesMedicineHumansProspective StudiesAdverse effectProspective cohort studyHippocampal sclerosisbusiness.industryMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyNeurologyTolerabilityEpilepsy Temporal LobeAnesthesiaConcomitantAnticonvulsantsDrug Therapy CombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesEpilepsybehavior : EB
researchProduct

Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic res…

2015

Abstract Objective This was a retrospective data analysis to evaluate the treatment response to enzyme replacement therapy (ERT) with Velaglucerase alfa using whole-body magnetic resonance imaging (MRI). Materials and methods A baseline and follow-up MRI were performed on 18 Gaucher Type 1 patients at an interval of 11.6 months. The MRI score systems determined the Bone-Marrow-Burden (BMB) score, the Dusseldorf-Gaucher score (DGS), and the Vertebra-Disc-Ratio (VDR). The Severity Score Index Type 1 (GD-DS3) was also assessed. Results The baseline MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.70; while, the follow-up MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.73. The baseline GD-…

0301 basic medicineAdultMalemedicine.medical_specialtyWhole body imagingSeverity of Illness Index03 medical and health sciences0302 clinical medicineBone MarrowStatistical significanceSeverity of illnessmedicineHumansEnzyme Replacement TherapyWhole Body ImagingStage (cooking)Molecular BiologyAgedRetrospective StudiesGaucher Diseasemedicine.diagnostic_testbusiness.industryVelaglucerase alfaPlatelet CountMagnetic resonance imagingRetrospective cohort studyCell BiologyHematologyEnzyme replacement therapyMiddle AgedMagnetic Resonance ImagingRecombinant ProteinsSurgery030104 developmental biologyTreatment OutcomeMolecular MedicineGlucosylceramidaseFemaleRadiologybusiness030215 immunologymedicine.drugFollow-Up StudiesBlood cells, moleculesdiseases
researchProduct